Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine

BACKGROUND: Prostatic acid phosphatase (PAP) is a prostate tumor antigen, and the target of the only FDA-approved anti-tumor vaccine, sipuleucel-T. We have previously reported in two clinical trials that a DNA vaccine encoding PAP (pTVG-HP) could elicit PAP-specific, Th1-biased T cells in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wargowski, Ellen, Johnson, Laura E., Eickhoff, Jens C., Delmastro, Lauren, Staab, Mary Jane, Liu, Glenn, McNeel, Douglas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850960/
https://www.ncbi.nlm.nih.gov/pubmed/29534736
http://dx.doi.org/10.1186/s40425-018-0333-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850960/
https://www.ncbi.nlm.nih.gov/pubmed/29534736
http://dx.doi.org/10.1186/s40425-018-0333-y

Ejemplares similares